Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
ConditionEpithelial Tumors, Malignant
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMyeloid Therapeutics
About this trial
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
Eligibility criteria
Qualifiers
Adults age ≥ 18 inclusive at the time the Informed Consent Form (ICF) is signed.
Urothelial
Cervical
Ovarian epithelial
Disqualifiers
Known active CNS metastasis and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression for at least 4 weeks by repeat imaging), clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of study intervention.
Pregnant or nursing women.
Must be > 28 days beyond major surgery, including hepatectomy or joint replacement.
Prior allogeneic bone marrow transplantation or solid organ transplant.
Trial design
Treatments tested in this trial
- MT-302 (A)
Treatment groups
48 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov